Gastrointestinal and Mucosal Research
Preclinical investigation of compounds studied for gut mucosal protection, intestinal repair, inflammatory bowel disease models, and gastrointestinal cytoprotection in rodent models.
Research Overview
Gastrointestinal and mucosal research examines peptide compounds studied in rodent models of gut injury, ulceration, inflammation, and mucosal barrier dysfunction. The primary model systems are chemical-induced gastric ulcer models (HCl, aspirin, ethanol, indomethacin) in Wistar and Sprague-Dawley rats, DSS-induced colitis in C57BL/6 mice, TNBS-induced colitis in Wistar rats, gut fistula models, intestinal anastomosis models, and intestinal epithelial cell cultures. The Sikiric laboratory at the University of Zagreb has established the most extensive gastrointestinal research literature for BPC-157, with more than 50 publications documenting cytoprotective effects across multiple GI injury paradigms spanning gastric ulceration, esophageal injury, small intestinal damage, colon fistula, and inflammatory bowel disease models in rats and mice. KPV mucosal research by the Larena and Turner groups has examined alpha-MSH receptor-mediated anti-inflammatory activity in intestinal epithelial cell cultures and murine colitis models.
Key Research Findings
Findings from preclinical in vitro and in vivo model systems. All summaries reference published research models.
Gastric Ulcer Protection in HCl and Ethanol Rat Models
Sikiric et al. documented dose-dependent reduction of gastric mucosal lesion area in Wistar rats treated with BPC-157 before or after HCl, ethanol, aspirin, and indomethacin challenge, with BPC-157-treated animals showing 50 to 90% reductions in macroscopic ulcer area compared to vehicle-treated challenged controls at multiple dose levels. Histological analysis confirmed reduced depth and area of mucosal damage and preserved epithelial continuity in BPC-157-treated gastric sections.
Colitis Modulation in DSS and TNBS Rodent Models
BPC-157 studies in DSS-induced colitis C57BL/6 mice documented reduced disease activity index scores (comprising weight loss, stool consistency, rectal bleeding), reduced colon shortening, and lower colon tissue cytokine levels (TNF-alpha, IL-1beta, IL-6) in BPC-157-treated animals compared to untreated DSS controls. Parallel TNBS colitis studies in Wistar rats documented similar patterns of reduced macroscopic and histological colitis severity in treated animals compared to vehicle controls.
Intestinal Fistula Healing in Rat Surgical Models
Sikiric and colleagues documented that BPC-157 administration in a rat colocutaneous fistula model significantly reduced time to fistula closure compared to vehicle-treated controls, with treated animals showing spontaneous fistula healing within 8 to 14 days that did not occur in vehicle controls at equivalent time points. Similar fistula healing effects were documented in esophago-colonic and jejunocutaneous fistula models in rats, suggesting mechanism activity across different intestinal fistula locations.
Mucosal Anti-Inflammatory Effects of KPV in Cell and Mouse Models
KPV (Lys-Pro-Val) anti-inflammatory activity in intestinal models was documented by Turner and colleagues using Caco-2 intestinal epithelial cells and in murine DSS colitis, with KPV-treated cells showing reduced NF-kB activation (measured by IkB phosphorylation and nuclear NF-kB translocation) and lower IL-8 secretion compared to untreated inflamed controls. DSS colitis studies in C57BL/6 mice showed reduced colon histological damage scores and lower mucosal cytokine levels in KPV-treated animals versus untreated DSS controls.
Compounds Studied in This Area
Research compounds with documented preclinical activity in this domain.
Research Connections
Broader Research Context
Gastrointestinal peptide research has produced one of the largest preclinical bodies of evidence for any compound class in the research peptide market, with the BPC-157 GI literature alone comprising more than 200 papers from the Sikiric group and collaborating laboratories across Europe and Asia. The diversity of GI injury models studied (gastric, esophageal, small intestinal, colonic) in multiple species (rats, mice) across multiple decades provides unusually strong convergent preclinical evidence for BPC-157 GI cytoprotective activity. The emerging KPV GI literature extends mucosal anti-inflammatory research to a distinct compound class acting through melanocortin receptor-mediated immune modulation rather than the nitric oxide pathway central to BPC-157 activity.
Research Questions
Continue Your Research
Browse all research areas or explore the full Research Library for compound comparisons, study indexes, and use case guides.